{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:14:22Z","timestamp":1789910062636,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>New regimens to shorten tuberculosis treatment and manage patients with drug-resistant tuberculosis who are infected with HIV are urgently needed. Experimental and clinical evidence suggests that the new drugs bedaquiline (B) and pretomanid (Pa), combined with an existing drug, pyrazinamide (Z), and a repurposed drug, clofazimine (C), may assist treatment shortening of drug-susceptible and drug-resistant tuberculosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the 14-day bactericidal activity of C and Z in monotherapy and in combinations with Pa and B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Groups of 15 treatment-naive, sputum smear\u2013positive patients with pulmonary tuberculosis were randomized to receive combinations of B with Z-C, Pa-Z, Pa-Z-C, and Pa-C, or C or Z alone, or standard combination treatment for 14 days. The primary endpoint was the mean daily fall in log10 \u00a0Mycobacterium tuberculosis CFU per milliliter sputum estimated by joint nonlinear mixed-effects Bayesian regression modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Estimated activities were 0.167 (95% confidence interval [CI], 0.075\u20130.257) for B-Pa-Z, 0.151 (95% CI, 0.071\u20130.232) for standard treatment, 0.124 (95% CI, 0.035\u20130.214) for B-Z-C, 0.115 (95% CI, 0.039\u20130.189) for B-Pa-Z-C, and 0.076 (95% CI, 0.005\u20130.145) for B-Pa-C. Z alone had modest activity (0.036; 95% CI, \u22120.026 to 0.099). C had no activity alone (\u22120.017; 95% CI, \u22120.085 to 0.053) or in combinations. Treatments were well tolerated and safe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>B-Pa-Z, including two novel agents without resistance in prevalent M. tuberculosis strains, is a potential new tuberculosis treatment regimen. C had no measurable activity in the first 14 days of treatment.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 01691534).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201410-1801oc","type":"journal-article","created":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T13:03:08Z","timestamp":1422277388000},"page":"943-953","source":"Crossref","is-referenced-by-count":188,"title":["Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline"],"prefix":"10.1093","volume":"191","author":[{"given":"Andreas H.","family":"Diacon","sequence":"first","affiliation":[{"name":"Division of Medical Physiology, MRC Centre for Tuberculosis Research, DST\/NRF Centre of Excellence for Biomedical Tuberculosis Research"},{"name":"Task Applied Science, Bellville, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Department of Medicine, University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"von Groote-Bidlingmaier","sequence":"additional","affiliation":[{"name":"Task Applied Science, Bellville, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Symons","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Department of Medicine, University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amour","family":"Venter","sequence":"additional","affiliation":[{"name":"MRC Centre for Tuberculosis Research, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Donald","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christo","family":"van Niekerk","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Everitt","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Hutchings","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divan A.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Mathematical Statistics and Actuarial Science, University of the Free State, Bloemfontein, South Africa; and"},{"name":"Quintiles Biostatistics, Bloemfontein, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schall","sequence":"additional","affiliation":[{"name":"Department of Mathematical Statistics and Actuarial Science, University of the Free State, Bloemfontein, South Africa; and"},{"name":"Quintiles Biostatistics, Bloemfontein, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.","family":"Mendel","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,4,15]]},"reference":[{"key":"2026032100222898400_bib1","author":"World Health Organization"},{"key":"2026032100222898400_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.00898-06","article-title":"Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis","volume":"51","author":"Ibrahim","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib3","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1128\/AAC.00686-08","article-title":"Enhanced bactericidal activity of rifampin and\/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis","volume":"52","author":"Tasneen","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib4","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1128\/AAC.00384-12","article-title":"Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis","volume":"56","author":"Williams","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial","volume":"380","author":"Diacon","year":"2012","journal-title":"Lancet"},{"key":"2026032100222898400_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100222898400_bib7","article-title":"14 day EBA study of PA-824, bedaquiline, pyrazinamide and clofazimine in smear positive TB patients","author":"Diacon"},{"key":"2026032100222898400_bib8","author":"International Union against Tuberculosis and Lung Disease"},{"key":"2026032100222898400_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","article-title":"The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease","volume":"53","author":"Fridericia","year":"1920","journal-title":"Acta Med Scand"},{"key":"2026032100222898400_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1113\/jphysiol.1920.sp001881","article-title":"The time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes","volume":"53","author":"Bazett","year":"1920","journal-title":"J Physiol"},{"key":"2026032100222898400_bib11","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1472-9792(08)70038-6","article-title":"The early bactericidal activity of anti-tuberculosis drugs: a literature review","volume":"88","author":"Donald","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"2026032100222898400_bib12","first-page":"213","article-title":"Early bactericidal activity of antituberculosis agents","author":"Diacon","year":"2011"},{"key":"2026032100222898400_bib13","first-page":"818","article-title":"Differentiation of Mycobacterium tuberculosis complex by PCR amplification of genomic regions of difference","volume":"10","author":"Warren","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026032100222898400_bib14","article-title":"A Bayesian non-linear mixed effects regression model for the characterization of early bactericidal activity of tuberculosis drugs","author":"Burger","journal-title":"J Biopharm Stat"},{"key":"2026032100222898400_bib15","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1128\/AAC.00774-05","article-title":"Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment","volume":"50","author":"Davies","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib16","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1128\/AAC.00112-09","article-title":"Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib17","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00106-09","article-title":"Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib18","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/AAC.06125-11","article-title":"Phase II dose-ranging trial of the early bactericidal activity of PA-824","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib19","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib20","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/AAC.02243-12","article-title":"Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis","volume":"57","author":"Diacon","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tube.2011.05.006","article-title":"Pyrazinamide pharmacokinetics and efficacy in adults and children","volume":"92","author":"Donald","year":"2012","journal-title":"Tuberculosis (Edinb)"},{"key":"2026032100222898400_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tube.2004.04.001","article-title":"Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid","volume":"84","author":"Nix","year":"2004","journal-title":"Tuberculosis (Edinb)"},{"key":"2026032100222898400_bib23","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"2026032100222898400_bib24","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1128\/JCM.03290-12","article-title":"Direct comparison of Xpert MTB\/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity","volume":"51","author":"Kayigire","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2026032100222898400_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1128\/AAC.40.3.633","article-title":"Antituberculosis activities of clofazimine and its new analogs B4154 and B4157","volume":"40","author":"Reddy","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib26","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/rccm.201304-0753OC","article-title":"Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice","volume":"188","author":"Grosset","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100222898400_bib27","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1128\/AAC.48.8.3133-3135.2004","article-title":"Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture","volume":"48","author":"Janulionis","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100222898400_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"Cholo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026032100222898400_bib29","doi-asserted-by":"crossref","first-page":"e004143","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"key":"2026032100222898400_bib30","first-page":"9","article-title":"Pharmacokinetics of clofazimine in healthy volunteers","volume":"55","author":"Schaad-Lanyi","year":"1987","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"2026032100222898400_bib31","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/art.21358","article-title":"Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus","volume":"52","author":"Bezerra","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026032100222898400_bib32","doi-asserted-by":"crossref","first-page":"e4009","DOI":"10.1371\/journal.pone.0004009","article-title":"Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes","volume":"3","author":"Ren","year":"2008","journal-title":"PLoS One"},{"key":"2026032100222898400_bib33","author":"Dannemann"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/191\/8\/943\/67215791\/ajrccm_191_8_943.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/191\/8\/943\/67215791\/ajrccm_191_8_943.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:22:35Z","timestamp":1774066955000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/191\/8\/943\/8504976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,4,15]]},"published-print":{"date-parts":[[2015,4,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201410-1801oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,4]]},"published":{"date-parts":[[2015,4]]}}}